MVT: In the News

Dr. Evan Unger Of Microvascular Therapeutics: 5 Things I Wish Someone Told Me Before I Became A Founder Dr. Evan Unger Of Microvascular Therapeutics: 5 Things I Wish Someone Told Me Before I Became A Founder | by Authority Magazine Editorial Staff | Authority Magazine | Dec, 2025 | Medium

December 4, 2025 — Salt Lake City, UT  — The Nucleus Institute’s investment committee has unanimously approved and completed an investment in Microvascular Therapeutics Inc. (MVT) through MVT’s convertible note. “This is our first institutional investor,” said Dr. Evan Unger, MD, CEO and Founder of MVT. “Their support is a strong validation of our investor readiness following Nucleus’ extensive due diligence.” “We are currently planning a priced round to fund a Phase III clin

Salt Lake City, UT –Wednesday November, 5 th  2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT) will be presenting new preclinical data demonstrating that focused ultrasound (FUS) using proprietary phase-shift microbubbles, NanoBlate (MVT-101), can selectively ablate brain tumors and open the blood-brain barrier (BBB) in targeted regions, potentially enabling safer, more precise, and non-invasive treatment for patients with malignant brain tum

Phase‑shift microbubble (also known as nanobubble) technology demonstrates robust thrombus resolution in a porcine deep vein thrombosis (DVT) model. Salt Lake City, UT – Microvascular Therapeutics, Inc. (MVT) today announced the publication of compelling preclinical data demonstrating that its proprietary phase‑shift microbubble platform, MVT‑101 (Solv), significantly enhances sonothrombolysis in a clinically relevant porcine model of deep vein thrombosis (DVT). The study app

Chicago, IL – October 7th, 2025 – Microvascular Therapeutics (MVT), a clinical-stage biopharmaceutical company pioneering innovations in...

Salt Lake City (Utah), September  29, 2025: Microvascular Therapeutics (MVT), the leader in development of next-generation ultrasound...

Nashville, TN – September 6, 2025  – Microvascular Therapeutics (MVT), a pioneering Utah-based biotechnology company, is honored to have...

Salt Lake City, UT – July 13, 2025  – Microvascular Therapeutics (MVT), a pioneering Utah based biotechnology company, is thrilled to...

Boston, MA – June 18, 2025 – Microvascular Therapeutics (MVT) is pleased to announce Founder and CEO, Dr. Evan Unger, as speaker on the...

May 14th, 2025 Salt Lake City, Utah: Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed...

Tucson, AZ & Mountain View, CA – Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased...

Microvascular Therapeutics, Inc. (MVT), and SoundJet Medical, Inc. (SoundJet) announce that they have entered into a strategic...

Tucson, AZ – Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the...

Tucson, AZ  - Dr. Evan Unger, CEO and Founder of Microvascular Therapeutics (MVT), has been awarded the 2024 Harry Fischer Award by...

Microvascular Therapeutics selected as a Participant in the 2024 Landmark Venture Forum [Tucson, AZ] – Microvascular Therapeutics Inc....

[Tucson, Arizona] – [2/05/2024] – Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing...

Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has...

Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment...